FDA's new Guidance Documents for 2012
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The U.S. Food and Drug Administration FDA has issued its yearly list of planned draft and final guidance documents for 2012. There are about 50 such guidance documents planned.
This is an overview about some important ones:
Biopharmaceutics and Biosimilarity:
- Scientific Considerations in Demonstrating Biosimilarity To a Reference Product
- Quality Considerations in Demonstrating Biosimilarity To a Reference Protein Product
Combination Products:
- Development of Drugs in Combination
cGMPs and Compliance:
- Control of Highly Potent Compounds
- Importation of Active Pharmaceutical Ingredients (API) for Use in Human Drugs
Labeling, Packaging and Supply Chain:
- Securing the Drug Supply Chain-Standards for Tracking and Tracing Prescription Drug Packages
- Pediatric Information: Incorporating into Human Prescription Drug and Biological Products Labeling
Source: FDA Guidance Agenda
Compiled by
Wolfgang Schmitt
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)
Related GMP News
26.08.2026GMP and "Planned Deviations" - a Contradiction?
19.08.2026Why Root Cause Analysis is the Key to efficient CAPA
19.08.2026EMA updates Guideline on implementing the Shortage Prevention Plan
19.08.2026FDA: Simplified Registration for U.S. Sites and Greater Complexity for Non-U.S. Sites
12.08.2026When Training Fails: FDA Warning Letters Highlight GMP Training Deficiencies in 2026
29.07.2026EU-GMP for Veterinary Medicinal Products: What will change in Switzerland?